We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Chairman’s Address to Shareholders 2020 Annual General Meeting
Chairman’s Address to Shareholders 2020 AGM
Read MoreAlterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new composition
Read More
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
Alterity Therapeutics today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the Uni
Read MoreAlterity completes Placement Tranche 1 raising $10M
$25M Second Tranche to complete following shareholder approval Alterity completes Tranche 1 of Placement raising $10M Tranche 2 completes on
Read MoreAlterity raises $35M in placement to international and Australian institutions and sophisticated investors.
Successfully obtained binding commitments for A$35M via institutional placement to be settled in 2 tranches Tranche 1: $10M raised under Alt
Read MoreNew data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that new clinical and experimental phar
Read MoreAlterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance fr
Read MoreAlterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has presented data on ATH434 (formerly PBT434) for the
Read MoreAlterity receives a $4.8 million R&D Tax Incentive Refund
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced that it has received a A$4.
Read MoreEuropean Commission approves Orphan Designation for Alterity’s lead drug candidate
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces that the European Commission (EC) has
Read MoreAlterity’s lead drug candidate receives positive opinion from European medical agency
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has received a positive opinion from the Europe
Read MoreAlterity presents clinical data on PBT434 at the 2019 MDS Congress
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Hum
Read MoreAlterity Therapeutics to Present at the Janney Healthcare Conference in New York
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Janney Healthcare Confe
Read MoreQuarterly Cash Flow Report
Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations
Read MoreAlterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully comple
Read More
Alterity Therapeutics talks to Finance News Network
Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug
Read MoreReceive news from Alterity Therapeutics
